The Centers for Disease Control and Prevention said Friday that MRNA from Moderna Inc.,
The COVID-19 vaccine produces an allergic reaction in a small percentage of people, similar to the Agency’s conclusions on the coronavirus vaccine developed by BioNTech SE BNTX,
and Pfizer Inc. PFE,
Moderna shares rose Monday by 1.6% in premarket trading. According to the CDC, there were 10 cases of anaphylaxis among the approximately 4 million doses administered between December 21 and January 10. Both vaccines are mRNA-based vaccines with similar efficacy rates in clinical trials. These are the only two COVID-19 vaccines that have been authorized in the US so far during the pandemic. The CDC has previously recommended that health care providers prepare for the possibility of anaphylaxis among people who are vaccinated. Moderna shares have risen 520.3% in the last 12 months, while the S&P 500 SPX,
it is increasing by 15.6%.